Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Oncology
Biotech
Kura, Kyowa hail ph. 2 win for leukemia drug, but hold back data
Kura and Kyowa claim to have scored a win for their oral leukemia treatment, while reassuring analysts about the lack of any hard data to prove it.
James Waldron
Feb 6, 2025 10:40am
OS buys full IP rights to its lead drug, gains 2 more assets
Jan 29, 2025 10:30am
Cullinan plans approval push for NSCLC drug after ph. 2 win
Jan 29, 2025 6:15am
OS' drug stopped lung cancer from returning in 3rd of patients
Jan 15, 2025 9:55am
Blueprint halts CDK2 inhibitor but pushes on in breast cancer
Jan 13, 2025 5:43am
Repare cans plans for phase 3 cancer combo trial
Jan 10, 2025 4:30am
More News
Candid adds another T-cell engager via $925M WuXi Biologics deal
Jan 7, 2025 8:42am
CytomX lays off 40%, mulls future of Amgen-partnered drug
Jan 7, 2025 7:56am
Investor pumps $3M into Cyclacel in return for CEO role
Jan 3, 2025 10:50am
Oncology biotech licenses Genevant tech for up to $123M
Dec 20, 2024 6:00am
See more stories